title: Tumor markers at the time of recurrence in patients with germ cell tumors.
abstract: BACKGROUND
  alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH) closely follow the course of germ cell tumors (GCTs) and are widely used for diagnosis, prognosis, and follow-up purposes. The objective of this study was to assess the concordance of tumor markers at the time of diagnosis and recurrence.
  
  
  METHODS
  The authors reviewed the records of 794 patients with GCTs treated in three Spanish hospitals from 1977-1996 and analyzed the concordance between AFP, HCG, and LDH levels at diagnosis and first and second recurrence. A positive marker was defined as a level of AFP > 10 ng/mL, HCG > 5 IU/L, or LDH > the upper limit of normal. One hundred twenty-five patients were identified who developed a first recurrence (123 had marker levels recorded). The median age was 27 years (range, 14-78 years). Histology was seminoma in 36 patients (29%) and nonseminomatous GCT (NSGCT) in 87 patients (71%).
  
  
  RESULTS
  Seventy-nine patients (64%) had elevated tumor markers at diagnosis and 76 (62%) at first recurrence. An elevated marker was present at first recurrence in 58 of 79 patients (73%) with initially positive markers and in 18 of 44 patients (41%) with initially negative markers. In 84 of 123 patients (68%), the same marker pattern (positive or negative) was present at the time of diagnosis and at first recurrence, 78% in seminomas and 64% in NSGCTs. The earliest indicator of recurrence was an elevated marker in patients with NSGCTs and a radiologic finding in patients with seminomas. Thirty patients developed a second recurrence, 27 of whom (90%) had the same marker pattern as at first recurrence.
  
  
  CONCLUSIONS
  Tumor marker pattern at diagnosis is not a good predictor of the pattern at recurrence, particularly in patients with NSGCTs. Marker assessment should be included in the follow-up schedule regardless of levels at the time of diagnosis. Early detection of recurrence should not rely only on marker levels, even in patients with elevated levels at presentation.
authors.affiliation: Servicio de Oncología Médica Hospital Universitario "Doce de Octubre," Madrid, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Trigo
authors.forename: J M
authors.initials: JM
authors.lastname: Tabernero
authors.forename: L
authors.initials: L
authors.lastname: Paz-Ares
authors.forename: J L
authors.initials: JL
authors.lastname: García-Llano
authors.forename: J
authors.initials: J
authors.lastname: Mora
authors.forename: P
authors.initials: P
authors.lastname: Lianes
authors.forename: E
authors.initials: E
authors.lastname: Esteban
authors.forename: R
authors.initials: R
authors.lastname: Salazar
authors.forename: J J
authors.initials: JJ
authors.lastname: López-López
authors.forename: H
authors.initials: H
authors.lastname: Cortés-Funes
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D006063:Chorionic Gonadotropin / Q000097:blood*; D018237:Germinoma / Q000097:blood* / Q000201:enzymology / Q000556:secondary*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D013030:Spain; D000509:alpha-Fetoproteins / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D007770:L-Lactate Dehydrogenase